Morepen Labs forms new subsidiary for medical devices

Written by Ruchika Sharma Published On 2021-09-30T11:00:03+05:30 | Updated On 26 Oct 2021 12:27 AM IST

Morepen Medtech name changed to Morepen Medipath

New Delhi: Morepen Laboratories Limited has announced carving out its point of care (POC) Medical Devices business into a newly incorporated wholly owned subsidiary, Morepen Devices Limited.

The shareholders have given their approval for the same on 28th September 2021 in the 36th Annual General Meeting (AGM) of the Company. The transfer of the business would happen as per terms of the Business Transfer Agreement to be signed between both the companies.

The Medical Devices (POC) business of the company has been delivering exponential growth for past many years. A stupendous growth of 71% was recorded in the previous financial year ending March 2021. The growth trends are being continued in Q1 FY'22 wherein POC business recorded a spectacular growth of 187%. Growing concerns for heath have pushed the average usage and consumption of diagnostics devices in every household multiple folds during last one and half year. It has been reflected in huge growth in sales revenues particularly last two years. The company expects the growth drivers will continue fuelling the higher consumption levels in the coming times.

"While the growth is stupendous, we believe this is only the tip of the iceberg. The Indian POC market is expected to touch US$ 16 billion by 2025 and we want to be the No 1 POC player in India with a very large part of our manufacturing being "Made in India", said Anubhav Suri, CEO, Medical Devices Business.

Mr. Anubhav Suri further added that the global POC market is expected to cross US$ 51 billion by 2025 and Morepen Devices is rightly placed to grab this opportunity by focusing on backward integration and cost leadership.

Sushil Suri, Chairman and Managing Director, said "Our POC Diagnostic business has surpassed even our own expectations and is gaining bigger share year after year in the total revenue of the company. Given that the business is scaling up so rapidly with the mainstreaming of POC business in India, we have to carve out a separate subsidiary both for building specialised teams to handle such scale and POC business unique skill sets."

"Given the scale we are looking to achieve, we will also explore bringing in fresh capital that makes it imperative to have a separate entity to undertake this huge initiative. It will also unlock the value of medical devices business segment of the company." Mr. Sushil Suri added.

-Mr. Anubhav Suri, CEO, Medical Devices Business added, "The number of POC Medical devices and home testing are growing at an exponential pace as technology and cost reduction has made it possible for doing tests at home that could only have been done in a lab before. We believe the number of POC Devices and tests will increase significantly over the next 3-4 years due to advances in biosensors and other rapid diagnostic technologies."

"Doctors now want patients to monitor their own health vitals and share the data over phone. That is just the first step of integrating this data directly to the doctors. The company is focusing on connected devices, data mining using artificial intelligence (AI), machine learning and also develop a data lab for connected devices", added Mr. Anubhav Suri.

"The new devices company will be scaling up its R&D teams to create world class R&D Centre for medical devices in India. The device company would also go for all relevant Certifications of its manufacturing facilities and products for exporting them to regulated markets in Europe and North America and plans to become a hub for manufacturing Point of care medical devices for the Global market. The new entity plans to deploy more resources on the R&D, backwards integration of core technologies like making enzymes /proteins," the company stated in its recent release.

Read also: Morepen Labs to transfer medical devices business to subsidiary via slump sale

morepen labsmorepen labs newsmedical devices

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751